Cadrenal Therapeutics, Inc. Common Stock
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Quang X. Pham
- Full Time Employees
- 5
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 822 A1A North Ponte Vedra FL United States of America 32082
- IPO Date
- Jan 20, 2023
- CIK
- 0001937993
- Website
- cadrenal.com
- Similar Companies
- Business
- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) is a clinical-stage biopharmaceutical company focused on developing novel anticoagulants that address critical gaps in acute and chronic anticoagulation therapy for high-risk cardiovascular patients, including those with end-stage kidney disease and atrial fibrillation, left ventricular assist devices, mechanical heart valves, and thrombotic antiphospholipid syndrome; its lead product candidate is tecarfarin, a late-stage, reversible oral vitamin K antagonist designed for greater reliability and stability in chronic anticoagulation compared to warfarin by avoiding CYP2C9 metabolism variability; the company also advances frunexian, a novel intravenous small-molecule Factor XIa inhibitor for safer acute hospital care, particularly in complex cardiac surgeries and critical settings where bleeding risks are elevated. Founded in 2022 and headquartered in Ponte Vedra, Florida, Cadrenal Therapeutics operates primarily in the United States with a pipeline targeting underserved orphan cardiovascular indications and maintains a collaboration with Abbott to evaluate tecarfarin in left ventricular assist device patients, alongside ongoing Phase 2 trial preparations in dialysis patients and completion of cGMP manufacturing for clinical supplies. In September 2025, the company enhanced its pipeline through the acquisition of eXIthera's portfolio of Factor XIa inhibitors, including frunexian, under terms providing up to $15 million in milestone payments and royalties on future global sales, positioning Cadrenal to deliver differentiated therapies across thrombotic risk spectrums while focusing capital on tecarfarin advancement and new assets.
Company News
Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia
Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process
Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor's Phase 3 Discontinuation
Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation
Cadrenal Therapeutics' Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress
Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress
Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease
Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026
Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event
Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA
Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)
Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting
Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes
Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Update
Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Up 22.1% in January